Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-26
2007-06-26
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S313000, C514S339000, C514S367000, C514S394000, C544S405000, C546S159000, C546S268100, C548S159000, C548S304700
Reexamination Certificate
active
10454939
ABSTRACT:
The present invention relates to compounds of the formula I, in which R1, R2, A, B, D, F, n, m and o have the meanings indicated herein. The compounds of the formula I are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb). They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of atherothrombotic diseases
REFERENCES:
patent: 5919776 (1999-07-01), Hagmann et al.
patent: 0 614 664 (1994-09-01), None
patent: 1 074 564 (2001-02-01), None
patent: WO 98/27815 (1998-07-01), None
Raynes et al. “Novel Bisquinoline Antimalarials” Biochemical Pharmacology, 1996, 551-559.
Trebst, A. “Measurement of Hill Reactions and Photoreduction” Meth Enzymol. 1972, vol. 24, 146-165.
Bundgaard, “Novel Chemical Approaches in Prodrug Design,”Drugs of the Future16:443-458 (1991).
Lanza et al., “Substituted 4,6-Diaminoquinolines as Inhibitors of C5a Receptor Binding,”J. Med. Chem.35:252-258 (1992).
Fleisher et al., “Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs,”Advanced Drug Delivery Reviews19:115-130 (1996).
Kageyama et al., “Anti-Human vWF Monoclonal Antibody, AJvW-2 Fab, Inhibits Repetitive Coronary Artery Thrombosis Without Bleeding Time Prolongation in Dogs,”Thrombosis Research101:395-404 (2001).
Fukuchi Naoyuki
Just Melitta
Klingler Otmar
Sakurai Kuniya
Ajinomoto Co. Inc
Clark & Elbing LLP
Elbing Karen L.
Kosack Joseph R.
Saeed Kamal A.
LandOfFree
Inhibitors of the GPIb—vWF interaction, their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of the GPIb—vWF interaction, their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of the GPIb—vWF interaction, their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3876495